From: Investor's Business Daily<ibd@ibd1.investors.com>
To: david@coronariversidehomes.com
Received: Wednesday, May 13, 2009 02:43 AM
IBD Tech Report Newsletter
Discover emerging trends and the companies driving them with IBD Tech Report View IBD Tech Report as a web page | Please add ibd@ibd1.investors.com to your address book.
Investor Carl Icahn wants the biotech to split in two, with one company focused on neurology and another on cancer. Icahn said separating Biogen's (BIIB) assets would enhance shareholder value. Icahn also said the neurology company could have generated $2.93 bil last year, the cancer firm $1.17 bil. He launched his second proxy battle for the company's board after losing a proxy fight with the company last year over the argument of finding a potential buyer. Biogen edged up 0.1% to 49.20.
The information contained herein is not and should not be construed as a solicitation to buy or sell any securities. Legal Disclaimer
Do not reply to this message, as it will not be received. For further assistance or to contact IBD, please visit www.investors.com. To update your email communication preferences click here.
You received this e-mail because you are currently subscribed to the Tech Report e-mail from Investor's Business Daily. Click here to unsubscribe.
Investor's Business Daily, IBD and CAN SLIM and their corresponding logos are registered trademarks of Data Analysis, Inc., an affiliate of Investor's Business Daily. Copyright and Trademark Notice.
